Share-based Payment Arrangement, Expense of Lineage Cell Therapeutics, Inc. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lineage Cell Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,199,000, a 9.8% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,969,000, a 3% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,077,000, a 9.4% increase from 2023.
  • Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4,640,000, a 8.2% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,287,000.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,969,000 $1,199,000 -$131,000 -9.8% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $5,100,000 $1,238,000 -$31,000 -2.4% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $5,131,000 $1,217,000 +$54,000 +4.6% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $5,077,000 $1,315,000 +$255,000 +24% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $4,822,000 $1,330,000 +$61,000 +4.8% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $4,761,000 $1,269,000 -$11,000 -0.86% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $4,772,000 $1,163,000 +$132,000 +13% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $4,640,000 $1,060,000 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $1,269,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,280,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,031,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2018 $123,000 -$850,000 -87% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2018 2018 Q3
Q1 2018 $984,000 -$42,000 -4.1% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2018 2018 Q1
Q3 2017 $4,552,000 $973,000 +$263,000 +37% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q2 2017 $4,289,000 $905,000 -$1,315,000 -59% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2017 2017 Q2
Q1 2017 $5,604,000 $1,026,000 -$2,347,000 -70% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2017 2017 Q1
Q4 2016 $7,951,000 $1,648,000 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2017 2016 FY
Q3 2016 $710,000 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $2,220,000 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $3,373,000 +$1,459,000 +76% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q1 2015 $1,914,000 +$1,112,446 +139% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q1 2014 $801,554 +$109,608 +16% 01 Jan 2014 31 Mar 2014 10-Q 12 May 2014 2014 Q1
Q1 2013 $691,946 +$218,512 +46% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q1 2012 $473,434 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013 2013 Q1

Lineage Cell Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,077,000 +$437,000 +9.4% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $4,640,000 +$353,000 +8.2% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $4,287,000 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2018 $298,000,000 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2016 $7,951,000 -$3,099,000 -28% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2017 2016 FY
2015 $11,050,000 +$6,595,000 +148% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2017 2016 FY
2014 $4,455,000 +$1,410,000 +46% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $3,045,000 +$1,201,038 +65% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $1,843,962 +$41,549 +2.3% 01 Jan 2012 31 Dec 2012 10-K 11 Mar 2015 2014 FY
2011 $1,802,413 +$708,682 +65% 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014 2013 FY
2010 $1,093,731 01 Jan 2010 31 Dec 2010 10-K 18 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.